252 related articles for article (PubMed ID: 24446140)
1. [Development costs, regulation and audit in the German SHI Drug Sector].
Kamp F; Walter P; Bücheler R
Gesundheitswesen; 2014 Jan; 76(1):7-18. PubMed ID: 24446140
[No Abstract] [Full Text] [Related]
2. Pharmaceuticals and medical devices: business practices.
Steiner DJ
Issue Brief Health Policy Track Serv; 2013 Dec; ():1-36. PubMed ID: 24482889
[No Abstract] [Full Text] [Related]
3. Realizing two-tiered innovation policy through drug regulation.
Ridgway WE
Stanford Law Rev; 2006 Feb; 58(4):1221-50. PubMed ID: 16685807
[No Abstract] [Full Text] [Related]
4. [Medications: dear and expensive?].
Rojahn J
Klin Monbl Augenheilkd; 2014 Feb; 231(2):108-13. PubMed ID: 25298981
[No Abstract] [Full Text] [Related]
5. A precarious balancing act--the role of the FDA as protector of public health and industry wealth.
McCabe AR
Suffolk Univ Law Rev; 2003; 36(3):787-819. PubMed ID: 16493844
[No Abstract] [Full Text] [Related]
6. Reanalyzing reverse payment settlements: a solution to the patentee's dilemma.
Wang Z
Cornell Law Rev; 2014 Jul; 99(5):1227-58. PubMed ID: 25112001
[No Abstract] [Full Text] [Related]
7. Generic drugs: the stalling game.
Consum Rep; 2001 Jul; 66(7):36-40. PubMed ID: 11725791
[TBL] [Abstract][Full Text] [Related]
8. Pharmaceuticals and medical devices: business practices. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-36. PubMed ID: 23297448
[No Abstract] [Full Text] [Related]
9. New drugs and indications in 2012. Sluggish progress, timid measures to protect patients.
Prescrire Int; 2013 Apr; 22(137):105-7. PubMed ID: 23662323
[TBL] [Abstract][Full Text] [Related]
10. Balancing government regulation against access to drugs: address to Seton Hall University School of Law, February 16, 2007.
Meron D
Seton Hall Law Rev; 2007; 37(4):929-39. PubMed ID: 18363219
[No Abstract] [Full Text] [Related]
11. Oncology pharmaceutical funding in New Zealand: a different approach and a proposal.
Beatty PA; Laking GR
J Oncol Pract; 2015 May; 11(3):249-51. PubMed ID: 25829524
[No Abstract] [Full Text] [Related]
12. Pharmaceuticals and medical devices: cost savings. Issue brief.
Steiner DJ
Issue Brief Health Policy Track Serv; 2012 Dec; ():1-33. PubMed ID: 23297446
[No Abstract] [Full Text] [Related]
13. Drug shortage crisis resolution.
Duffy E
J Pharm Pract; 2012 Dec; 25(6):619-20. PubMed ID: 23222856
[No Abstract] [Full Text] [Related]
14. Congress, the FDA, and the fair development of new medications for children.
McKinney RE
Pediatrics; 2003 Sep; 112(3 Pt 1):669-70. PubMed ID: 12949299
[No Abstract] [Full Text] [Related]
15. Medicines pricing singled out.
Buchanan E
S Afr Med J; 2004 May; 94(5):334. PubMed ID: 15211941
[No Abstract] [Full Text] [Related]
16. New rules for US drug reimbursement.
Bouchie A
Nat Biotechnol; 2003 Oct; 21(10):1119-20. PubMed ID: 14520382
[No Abstract] [Full Text] [Related]
17. The ongoing regulation of generic drugs.
Frank RG
N Engl J Med; 2007 Nov; 357(20):1993-6. PubMed ID: 18003956
[No Abstract] [Full Text] [Related]
18. The consumer welfare implications of governmental policies and firm strategy in markets for medicines.
Chatterjee C; Kubo K; Pingali V
J Health Econ; 2015 Dec; 44():255-73. PubMed ID: 26581076
[TBL] [Abstract][Full Text] [Related]
19. The FDA and the pharmaceutical industry: is regulation contributing to drug shortage?
Roman A
Albany Law Rev; 2013-2014; 77(2):539-77. PubMed ID: 24851322
[No Abstract] [Full Text] [Related]
20. [Reference prices].
Rey Abella ME
Aten Primaria; 1999 Sep; 24(5):252-4. PubMed ID: 10590555
[No Abstract] [Full Text] [Related]
[Next] [New Search]
